Cvrx Inc (CVRX)

$9.36

-0.15

(-1.58%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $9.13
    $9.55
    $9.36
    downward going graph

    2.51%

    Downside

    Day's Volatility :4.4%

    Upside

    1.94%

    downward going graph
  • $6.40
    $33.14
    $9.36
    downward going graph

    31.62%

    Downside

    52 Weeks Volatility :80.69%

    Upside

    71.76%

    downward going graph

Returns

PeriodCvrx IncSector (Health Care)Index (Russel 2000)
3 Months
-36.28%
6.4%
0.0%
6 Months
-64.88%
6.0%
0.0%
1 Year
-43.92%
9.6%
0.0%
3 Years
-52.96%
14.8%
-19.4%

Highlights

Market Capitalization
205.4M
Book Value
$3.07
Earnings Per Share (EPS)
-2.48
Wall Street Target Price
14.0
Profit Margin
-123.58%
Operating Margin TTM
-206.43%
Return On Assets TTM
-29.04%
Return On Equity TTM
-62.7%
Revenue TTM
42.1M
Revenue Per Share TTM
2.02
Quarterly Revenue Growth YOY
35.0%
Gross Profit TTM
17.5M
EBITDA
-52.6M
Diluted Eps TTM
-2.48
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.5
EPS Estimate Next Year
-1.98
EPS Estimate Current Quarter
-0.54
EPS Estimate Next Quarter
-0.5

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Cvrx Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 49.57%

Current $9.36
Target $14.00

Company Financials

FY19Y/Y Change
Revenue
6.3M
-
Net Income
-14.6M
-
Net Profit Margin
-233.87%
-
FY20Y/Y Change
Revenue
6.1M
↓ 3.26%
Net Income
-14.1M
↓ 3.58%
Net Profit Margin
-233.09%
↑ 0.78%
FY21Y/Y Change
Revenue
13.0M
↑ 115.36%
Net Income
-43.1M
↑ 205.32%
Net Profit Margin
-330.45%
↓ 97.36%
FY22Y/Y Change
Revenue
22.5M
↑ 72.36%
Net Income
-41.4M
↓ 3.83%
Net Profit Margin
-184.38%
↑ 146.07%
FY23Y/Y Change
Revenue
39.3M
↑ 74.89%
Net Income
-41.2M
↓ 0.55%
Net Profit Margin
-104.85%
↑ 79.53%
Q4 FY22Q/Q Change
Revenue
7.2M
↑ 16.0%
Net Income
-10.5M
↑ 7.18%
Net Profit Margin
-146.82%
↑ 12.09%
Q1 FY23Q/Q Change
Revenue
8.0M
↑ 11.19%
Net Income
-11.4M
↑ 7.95%
Net Profit Margin
-142.55%
↑ 4.27%
Q2 FY23Q/Q Change
Revenue
9.5M
↑ 19.06%
Net Income
-11.7M
↑ 2.44%
Net Profit Margin
-122.64%
↑ 19.91%
Q3 FY23Q/Q Change
Revenue
10.5M
↑ 10.64%
Net Income
-9.0M
↓ 22.66%
Net Profit Margin
-85.73%
↑ 36.91%
Q4 FY23Q/Q Change
Revenue
11.3M
↑ 7.55%
Net Income
-9.2M
↑ 1.69%
Net Profit Margin
-81.05%
↑ 4.68%
Q1 FY24Q/Q Change
Revenue
10.8M
↓ 4.73%
Net Income
-22.2M
↑ 142.13%
Net Profit Margin
-206.0%
↓ 124.95%
FY19Y/Y Change
Total Assets
29.1M
-
Total Liabilities
308.2M
-
FY20Y/Y Change
Total Assets
64.8M
↑ 122.55%
Total Liabilities
358.0M
↑ 16.18%
FY21Y/Y Change
Total Assets
152.5M
↑ 135.5%
Total Liabilities
6.6M
↓ 98.16%
FY22Y/Y Change
Total Assets
124.9M
↓ 18.1%
Total Liabilities
15.8M
↑ 139.14%
FY23Y/Y Change
Total Assets
115.2M
↓ 7.77%
Total Liabilities
39.3M
↑ 149.3%
Q4 FY22Q/Q Change
Total Assets
124.9M
↓ 1.29%
Total Liabilities
15.8M
↑ 89.11%
Q1 FY23Q/Q Change
Total Assets
122.7M
↓ 1.8%
Total Liabilities
23.0M
↑ 46.28%
Q2 FY23Q/Q Change
Total Assets
115.0M
↓ 6.29%
Total Liabilities
25.0M
↑ 8.5%
Q3 FY23Q/Q Change
Total Assets
106.4M
↓ 7.45%
Total Liabilities
23.6M
↓ 5.73%
Q4 FY23Q/Q Change
Total Assets
115.2M
↑ 8.29%
Total Liabilities
39.3M
↑ 66.61%
Q1 FY24Q/Q Change
Total Assets
106.2M
↓ 7.86%
Total Liabilities
39.9M
↑ 1.6%
FY19Y/Y Change
Operating Cash Flow
-12.8M
-
Investing Cash Flow
-106.0K
-
Financing Cash Flow
29.5M
-
FY20Y/Y Change
Operating Cash Flow
-16.1M
↑ 25.9%
Investing Cash Flow
-311.0K
↑ 193.4%
Financing Cash Flow
49.8M
↑ 68.48%
FY21Y/Y Change
Operating Cash Flow
-27.7M
↑ 72.29%
Investing Cash Flow
-1.2M
↑ 280.39%
Financing Cash Flow
111.9M
↑ 124.74%
FY22Y/Y Change
Operating Cash Flow
-42.7M
↑ 53.89%
Investing Cash Flow
-685.0K
↓ 42.1%
Financing Cash Flow
7.5M
↓ 93.3%
Q4 FY22Q/Q Change
Operating Cash Flow
-10.8M
↓ 2.3%
Investing Cash Flow
-79.0K
↓ 70.08%
Financing Cash Flow
7.1M
↑ 101571.43%
Q1 FY23Q/Q Change
Operating Cash Flow
-10.2M
↓ 5.46%
Investing Cash Flow
-240.0K
↑ 203.8%
Financing Cash Flow
7.6M
↑ 6.34%
Q2 FY23Q/Q Change
Operating Cash Flow
-12.8M
↑ 24.97%
Investing Cash Flow
-143.0K
↓ 40.42%
Financing Cash Flow
473.0K
↓ 93.75%

Technicals Summary

Sell

Neutral

Buy

Cvrx Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cvrx Inc
Cvrx Inc
-15.75%
-64.88%
-43.92%
-52.96%
-49.51%
Stryker Corporation
Stryker Corporation
-0.12%
8.84%
15.17%
33.61%
63.53%
Boston Scientific Corp.
Boston Scientific Corp.
0.73%
27.69%
45.08%
81.26%
82.49%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-2.63%
15.09%
-6.64%
-18.84%
33.76%
Abbott Laboratories
Abbott Laboratories
-4.26%
-10.65%
-8.76%
-14.07%
15.85%
Medtronic Plc
Medtronic Plc
-0.86%
-8.08%
-11.05%
-36.67%
-21.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cvrx Inc
Cvrx Inc
0.14
NA
NA
-2.5
-0.63
-0.29
NA
3.07
Stryker Corporation
Stryker Corporation
37.9
37.9
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.49
63.49
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
36.97
36.97
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
31.57
31.57
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
29.42
29.42
1.52
5.2
0.07
0.04
0.03
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cvrx Inc
Cvrx Inc
Buy
$205.4M
-49.51%
0.14
-123.58%
Stryker Corporation
Stryker Corporation
Buy
$126.2B
63.53%
37.9
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$111.1B
82.49%
63.49
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.1B
33.76%
36.97
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$174.1B
15.85%
31.57
13.96%
Medtronic Plc
Medtronic Plc
Buy
$104.1B
-21.49%
29.42
11.36%

Insights on Cvrx Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 11.30M → 10.77M (in $), with an average decrease of 4.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -9.01M → -22.18M (in $), with an average decrease of 71.9% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 45.1% return, outperforming this stock by 89.0%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 81.3% return, outperforming this stock by 134.3%

Institutional Holdings

  • Johnson & Johnson

    19.00%
  • NEA Management Company, LLC

    10.98%
  • BlackRock Inc

    3.54%
  • Balyasny Asset Management LLC

    2.86%
  • Vanguard Group Inc

    2.75%
  • Lord, Abbett & Co LLC

    2.73%

Company Information

cvrx is a private company located in minneapolis, minnesota. the company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. the barostim neo™ uses cvrx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat these conditions. the barostim neo can be adjusted to meet each patient’s individual therapy needs.

Organization
Cvrx Inc
Employees
200
CEO
Mr. Kevin Hykes
Industry
Healthcare

FAQs